Hiroto Ishii

Dr. Hiroto Ishii

Jikei University School of Medicine, Tokyo, Japan
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
HIHiroto Ishii
Hiroto Ishii
SYShingo Yano
Shingo Yano
Acute myeloid leukemia (AML) is a genetically heterogeneous hematological malignancy. Chromosomal and genetic analyses are important for the diagnosis and prognosis of AML. Some patients experience relapse or have refractory disease, despite conventional cytotoxic chemotherapies and allogeneic transplantation, and a variety of new agents and treatment strategies have emerged. After over 20 years during which no new drugs became available for the treatment of AML, the CD33-targeting antibody–drug conjugate gemtuzumab ozogamicin was developed. This is currently used in combination with standard chemotherapy or as a single agent. CPX-351, a liposomal formulation containing daunorubicin and cytarabine, has become one of the standard treatments for secondary AML in the elderly. FMS-like tyrosine kinase 3 (FLT3) inhibitors and isocitrate dehydrogenase 1/2 (IDH 1/2) inhibitors are mainly used for AML patients with actionable mutations. In addition to hypomethylating agents and venetoclax, a B-cell lymphoma-2 inhibitor is used in frail patients with newly diagnosed AML. Recently, tumor protein p53 inhibitors, cyclin-dependent kinase inhibitors, and NEDD8 E1-activating enzyme inhibitors have been gaining attention, and a suitable strategy for the use of these drugs is required. Antibody drugs targeting cell-surface markers and immunotherapies, such as antibody–drug conjugates and chimeric antigen receptor T-cell therapy, have also been developed for AML.

15 July 2022 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
HIHiroto Ishii
Hiroto Ishii
TSTomohiko Sato
Tomohiko Sato
MIMiyuki Ishibashi
Miyuki Ishibashi
HYHiroki Yokoyama
Hiroki Yokoyama
TSTakeshi Saito
Takeshi Saito
SYShingo Yano
Shingo Yano
We report the first case of immune complex type hemolytic anemia by initial micafungin administration that was given as prophylaxis to a 42-year-old Japanese man receiving chemotherapy for primary amyloidosis. The few cases found in the literature were associated with secondary administration causing immune hemolytic attacks. Despite its rarity, the present case calls for increased awareness of micafungin-induced hemolytic anemia upon initial administration.

1 May 2026 in Translational Cancer Research
Verified
Journal Article
Open access
HIHiroto Ishii
Hiroto Ishii
SIShoko Ishii
Shoko Ishii
YAYasuhiro Arakawa
Yasuhiro Arakawa
SYShingo Yano
Shingo Yano

7 April 2025 in Dermatology Reports
Verified
Journal Article
Open access
PDF file
MIMunenari Itoh
Munenari Itoh
SOSayaka Oshima
Sayaka Oshima
HIHiroto Ishii
Hiroto Ishii
SYShingo Yano
Shingo Yano
AAAkihiko Asahina
Akihiko Asahina
YNYoshimasa Nobeyama
Yoshimasa Nobeyama
Mycosis fungoides (MF) is a major variant of primary cutaneous T-cell lymphoma (CTCL) characterized by infiltration of neoplastic T cells in the epidermis and dermis. This disease progresses gradually and rarely reaches an advanced stage. Once advanced, MF is nearly impossible to treat due to limited therapeutic options. However, allogeneic hematopoietic stem cell transplantation (allo-HSCT) has recently emerged as a potential treatment. Among hematopoietic stem cell (HSC) sources, umbilical cord blood transplantation (UCBT) offers significant advantages. Despite its potential, there are challenges in applying UCBT to adults, and there are only a few reports on its use for MF. We report a Japanese case of advanced MF maintaining complete remission (CR) with UCBT and review previous cases of CTCL, including MF, treated with UCBT.

8 September 2025 in Hematological Oncology
Verified
Journal Article
Closed access
AIAkihiko Izumi
Akihiko Izumi
TTTakayoshi Tachibana
Takayoshi Tachibana
HIHiroto Ishii
Hiroto Ishii
SFShin‐Ichiro Fujiwara
Shin‐Ichiro Fujiwara
YNYuho Najima
Yuho Najima
YKYoshinobu Kanda
Yoshinobu Kanda

1 January 2021 in BLOOD CELL THERAPY / The official journal of APBMT
Verified
Journal Article
Open access
HIHiroto Ishii
Hiroto Ishii
HYHiroki Yokoyama
Hiroki Yokoyama
AKAtsushi Katsube
Atsushi Katsube
TGTadahiro Gunji
Tadahiro Gunji
TSTakeshi Saito
Takeshi Saito
SYShingo Yano
Shingo Yano
Posttransplant treatment is performed to treat hematopoietic diseases but can lead to allogeneic-specific complications in addition to those seen in a non-transplant setting. Immunomodulatory drugs (IMiDs) activate cytotoxic T cells and suppress regulatory T cells. The optimal timing and optimal dose of IMiDs after allogeneic transplantation (allo-HSCT) to reduce complications and increase antitumor efficacy are difficult to determine because the degree of recovery of donor immune cells varies depending on the time after allo-HSCT.